-
10:03:08 PM

APLIF Stock News

11/14/22 7:45 AM
OTC : APLIF
partnership
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the U.S. Department of Defense, via the Joint Science and Technology Office of the Defense Threat Reduction Agency in partnership with the U.S. Air Force Academy, will provide at least US $14 million in funding over...
RHEA-AI
neutral
11/10/22 7:38 AM
OTC : APLIF
earnings
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the second quarter of its fiscal year 2023, which ended on September 30, 2022. “We continue to move significantly closer to being able to provide a safe and effective vaccine...
RHEA-AI
neutral
08/12/22 4:54 PM
OTC : APLIF
earnings
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its fiscal year 2023, which ended on June 30, 2022. “As threats from both known and emerging infectious diseases loom around the world, I’ m proud that Appili...
RHEA-AI
neutral
04/27/22 7:37 AM
OTC : APLIF
conferences
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced that Stéphane Paquette, Vice President, Corporate Development, will present at the Bloom Burton& Co. Healthcare Investor Conference taking place on May 2 and 3, 2022.. Date: Tuesday, May 3, 2022 Time: 3:00 pm ET Location: Metro Toronto...
RHEA-AI
neutral
03/29/22 7:36 AM
OTC : APLIF
Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone Holdings
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced that it has entered into a senior secured loan and exclusive license and distribution agreement with Long Zone Holdings Inc., led by Jonathan Ross Goodman, founder of both Paladin Labs Inc. and Knight Therapeutics Inc..
RHEA-AI
positive
02/28/22 7:40 AM
OTC : APLIF
Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced that the U.S. Department of Defense, via the Joint Science and Technology Office of the Defense Threat Reduction Agency, has selected for funding an Appili proposal that would provide over US $10 million to advance the Company’ s...
RHEA-AI
neutral